0000914190-21-000213.txt : 20210810
0000914190-21-000213.hdr.sgml : 20210810
20210810181954
ACCESSION NUMBER: 0000914190-21-000213
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210806
FILED AS OF DATE: 20210810
DATE AS OF CHANGE: 20210810
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eansor Norman David
CENTRAL INDEX KEY: 0001270905
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17272
FILM NUMBER: 211161379
MAIL ADDRESS:
STREET 1: 8100 SOUTHPARK WAY, A-8
CITY: LITTLETON
STATE: CO
ZIP: 80120
FORMER NAME:
FORMER CONFORMED NAME: EANSOR N DAVID
DATE OF NAME CHANGE: 20031120
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIO-TECHNE Corp
CENTRAL INDEX KEY: 0000842023
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 411427402
STATE OF INCORPORATION: MN
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 614 MCKINLEY PL N E
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
BUSINESS PHONE: 6123798854
MAIL ADDRESS:
STREET 1: 614 MCKINLEY PLACE NE
CITY: MINNEAPOLIS
STATE: MN
ZIP: 55413
FORMER COMPANY:
FORMER CONFORMED NAME: TECHNE CORP /MN/
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2021-08-06
0000842023
BIO-TECHNE Corp
TECH
0001270905
Eansor Norman David
8100 SOUTHPARK WAY, A-8
LITTLETON
CO
80120
0
1
0
0
President-Protein Sciences
Common Stock
2021-08-08
4
M
0
2537
0
A
3855
D
Common Stock
2021-08-08
4
F
0
999
481.82
D
2856
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
11982
11982
D
Stock Options (Right to Buy)
125.05
2024-08-09
Common Stock
15976
15976
D
Restricted Stock Units
2021-08-08
4
M
0
2537
0
D
Common Stock
2537
0
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
13550
13550
D
Stock Options (Right to Buy)
177.32
2025-08-08
Common Stock
18066
18066
D
Restricted Stock Units
Common Stock
3151
3151
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
15948
15948
D
Stock Options (Right to Buy)
190.41
2026-08-07
Common Stock
21265
21265
D
Restricted Stock Units
Common Stock
2575
2575
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
11488
11488
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
15318
15318
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
24975
24975
D
Stock Options (Right to Buy)
267.87
2027-08-05
Common Stock
24975.0
24975.0
D
Restricted Stock Units
2021-08-06
4
A
0
1556
0
A
Common Stock
1556
1556
D
Stock Options (Right to Buy)
481.82
2021-08-06
4
A
0
6080
0
A
2028-08-06
Common Stock
6080
6080
D
Stock Options (Right to Buy)
481.82
2021-08-06
4
A
0
8107
0
A
2028-08-06
Common Stock
8107
8107
D
Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Fully exercisable.
Vested in full on 8/8/2021 upon the certification of achievement of performance goals.
Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.
/s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.
2021-08-10